Self archiving policy Final Author Version (accepted manuscript)When a research paper is accepted for publication in an NPG journal, authors are encouraged to submit the Final Author Version (the authors' accepted version of their manuscript) to PubMedCentral or other appropriate funding body's archive, for public release six months after first publication. In addition, authors are encouraged to archive this version of the manuscript in their institution's repositories and, if they wish, on their personal websites, also six months after the original publication. Authors should cite the publication reference and DOI number on the first page of any deposited version, and provide a link from it to the URL of the published article on the journal's website.Where journals publish content online ahead of publication in a print issue (known as advanced online publication, or AOP), authors may make the archived version openly available six months after first online publication (AOP).
ABSTRACTThe chemokine receptor CCR7 is widely implicated in breast cancer pathobiology.Although recent reports correlated high CCR7 levels with more advanced tumor grade and poor prognosis, limited in vivo data is available regarding its specific function in mammary gland neoplasia and the underlying mechanisms involved. To address these questions we generated a MMTV-PyMT Ccr7 -/-bigenic mouse breast cancer model which revealed that CCR7 ablation results in a considerable delay in tumor onset as well as significantly reduced tumor burden. Importantly, CCR7 was found to exert its function by regulating mammary cancer stem-like cells in both murine and human tumors. In vivo experiments showed that loss of CCR7 activity either through deletion or pharmacological antagonism significantly decreased functional pools of stem-like cells in mouse primary mammary tumors, providing a mechanistic explanation for the tumor-promoting role of this chemokine receptor. These data characterize the oncogenic properties of CCR7 in mammary epithelial neoplasia and point to a new route for therapeutic intervention to target evasive cancer stem cells.